Table 2 Molecular subtypes of breast cancer in patients younger than 40 years) and forty years or older
Age group in years | p-value | ||
|---|---|---|---|
< 40 | ≥ 40 | ||
Molecular subtype | |||
Luminal A | 55 (11.30%) | 209 (10.80%) | 0.78 |
Luminal B (HER2 positive) | 46 (9.40%) | 182 (9.40%) | 0.998 |
Luminal B (HER2 negative) | 93 (19.10%) | 427 (22.10%) | 0.141 |
HER2-enriched | 54 (11.10%) | 225 (11.70%) | 0.715 |
TNBC | 129 (26.40%) | 469 (24.30%) | 0.329 |
Others | 111 (22.70%) | 418 (21.70%) | 0.604 |
Total | 488 (100%) | 1930 (100%) | 0.476 |
Receptor status versus HER2 equivocal | |||
Positive (ER+/PR+, ER−/PR+, ER+/PR−) | 61 (55.00%) | 257 (61.50%) | 0.213 |
Negative (ER−/PR−) | 50 (45.00%) | 161 (38.50%) | |
Total | 111 (100%) | 418 (100%) | |